SRR1516063
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.310
- TGF_BETA_SIGNALING+0.260
- XENOBIOTIC_METABOLISM+0.030
- KRAS_SIGNALING_DN+0.020
- ESTROGEN_RESPONSE_EARLY-0.010
- SPERMATOGENESIS-0.020
- WNT_BETA_CATENIN_SIGNALING-0.020
- HEME_METABOLISM-0.050
- NOTCH_SIGNALING-0.070
- APICAL_SURFACE-0.090
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.550
- MYC_TARGETS_V2-0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- INFLAMMATORY_RESPONSE-0.480
- IL6_JAK_STAT3_SIGNALING-0.460
- ALLOGRAFT_REJECTION-0.440
- MYC_TARGETS_V1-0.440
- INTERFERON_ALPHA_RESPONSE-0.430
- INTERFERON_GAMMA_RESPONSE-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516050 | — | — | 0.921 |
| 2 | C3N-03420 | — | cohortA1 | 0.921 |
| 3 | SRR8942980 | — | — | 0.910 |
| 4 | SRR1516072 | — | — | 0.910 |
| 5 | TCGA-G2-A3IE-01A-11R-A20F-07 | — | — | 0.910 |
| 6 | SRR23303736 | — | — | 0.905 |
| 7 | MDT-AP-0153 | Med | Medulloblastoma | 0.903 |
| 8 | SRR33346948 | — | — | 0.896 |
| 9 | TCGA-CF-A47X-01A-31R-A23W-07 | — | — | 0.896 |
| 10 | SRR8943010 | — | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 4 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |